| Name | Title | Contact Details |
|---|
Acutus Medical is committed to pioneering a breakthrough technology to optimize the treatment strategies for complex cardiac arrhythmias by developing innovative, safe, efficacious, and cost-effective solutions for individuals suffering from these complex cardiac arrhythmias. Our mission is to develop and market a platform technology of safe, cost-effective and clinically advanced tools for the minimally invasive diagnosis (mapping) of complex arrhythmias (Atrial Fibrillation and Ventricular Tachycardia) that enable Physicians to optimize treatments and expand the ablation/therapeutic markets. In the pursuit of our mission, we will conduct all of our activities with the highest integrity and strive to become the world’s most valued company within the markets we serve to patients, customers, colleagues, investors, business partners, employees, and the communities in which we work and live.
Clinimed is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women`s health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 8,000 employees with products sold in over 100 countries.